A. Jarkowski

发表

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lawrence H. Schwartz, Donald A. Berry, Janis M. Taube, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A new era for castrate resistant prostate cancer: A treatment review and update

A. Jarkowski, M. Fong, R. Hare, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A Re-assessment of the Safety and Efficacy of Interleukin-2 for the Treatment of Renal Cell Carcinoma

A. Jarkowski, M. Wong, 2009 .

Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing

Neang S. Ly, Brian T. Tsuji, J. Bulitta, 2010, Pharmacotherapy.

Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia

A. Jarkowski, Richard P. Sweeney, 2008, Pharmacotherapy.

BRAF and beyond: Tailoring strategies for the individual melanoma patient

N. Khushalani, A. Jarkowski, 2014, Journal of carcinogenesis.

Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia – easier said than done? A case report

A. Jarkowski, Fouad Al-Najjar, 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

P. Ascierto, J. Larkin, M. Sznol, 2020, Future oncology.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

A. Jimeno, M. Fenton, I. Braña, 2019, European journal of cancer.

1042ODurvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

A. Jimeno, G. Melillo, N. Ready, 2017 .

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

I. Braña, L. Siu, J. Gilbert, 2019, JAMA oncology.

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

N. Agarwal, E. Lam, T. Olencki, 2014, Journal of immunotherapy.

Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings*

N. Khushalani, A. Jarkowski, Karen L Vona, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature

K. May, J. Kane, J. Skitzki, 2016, American journal of clinical oncology.

Immunotherapy in Melanoma

N. Khushalani, A. Jarkowski, Megan M. Saraceni, 2015, Journal of pharmacy practice.

Controversies in the Management of Advanced Melanoma

A. Jarkowski, L. Norris, V. Trinh, 2014, The Annals of pharmacotherapy.

Heart Failure Caused by Molecularly Targeted Therapies for Cancer

M. Wong, A. Jarkowski, A. Glode, 2011, Pharmacotherapy.

Response to Sorafenib After Sunitinib‐Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature

A. Jarkowski, M. Wong, 2009, Pharmacotherapy.

Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.

A. Jarkowski, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia

A. Jarkowski, Ashley E. Glode, Ashley E. Glode, 2009, Pharmacotherapy.

Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population

M. Wetzler, E. Wang, A. Forrest, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.

N. Khushalani, A. Jarkowski, N. Wilkinson, 2011, Anticancer research.

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

R. Ferris, G. Melillo, L. Licitra, 2015, Journal of Immunotherapy for Cancer.

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR

J. Gilbert, G. Melillo, H. Mehanna, 2015, Journal of Immunotherapy for Cancer.

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).

P. Ascierto, J. Larkin, M. Sznol, 2019, Journal of Clinical Oncology.

Response to Sorafenib After Sunitinib‐Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature

A. Jarkowski, M. Wong, 2009, Pharmacotherapy.